Perspective Therapeutics, Inc. (CATX)

Market Cap	155.37M
Revenue (ttm)	1.08M
Net Income (ttm)	-105.80M
Shares Out	74.34M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,923,914
Open	2.120
Previous Close	2.120
Day's Range	1.955 - 2.169
52-Week Range	1.600 - 5.388
Beta	1.22
Analysts	Strong Buy
Price Target	11.73 (+461.24%)
Earnings Date	Nov 10, 2025

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 140
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2024, Perspective Therapeutics's revenue was $1.45 million, an increase of 1.39% compared to the previous year's $1.43 million. Losses were -$79.28 million, 70.5% more than in 2023.

Analyst Summary

According to 11 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $11.73, which is an increase of 461.24% from the latest price.

Price Target

$11.73

(461.24% upside)

Analyst Consensus: Strong Buy